Two Sigma Investments LP Sells 57,599 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Two Sigma Investments LP decreased its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 11.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 424,537 shares of the company's stock after selling 57,599 shares during the period. Two Sigma Investments LP owned approximately 0.54% of Viridian Therapeutics worth $8,138,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. FMR LLC grew its stake in shares of Viridian Therapeutics by 6.2% in the 4th quarter. FMR LLC now owns 11,881,912 shares of the company's stock worth $227,776,000 after acquiring an additional 698,434 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Viridian Therapeutics by 4.0% during the fourth quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company's stock valued at $88,087,000 after purchasing an additional 174,952 shares in the last quarter. Deep Track Capital LP boosted its holdings in Viridian Therapeutics by 20.6% during the fourth quarter. Deep Track Capital LP now owns 4,522,741 shares of the company's stock worth $86,701,000 after purchasing an additional 771,796 shares during the last quarter. Tang Capital Management LLC boosted its holdings in Viridian Therapeutics by 11.1% during the fourth quarter. Tang Capital Management LLC now owns 2,492,925 shares of the company's stock worth $47,789,000 after purchasing an additional 250,000 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in Viridian Therapeutics by 3.8% during the fourth quarter. Alliancebernstein L.P. now owns 2,286,994 shares of the company's stock worth $43,842,000 after purchasing an additional 84,255 shares during the last quarter.

Viridian Therapeutics Stock Performance

Shares of NASDAQ:VRDN traded down $0.43 during mid-day trading on Wednesday, reaching $13.50. The company had a trading volume of 1,075,194 shares, compared to its average volume of 1,190,940. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The firm has a market cap of $1.10 billion, a price-to-earnings ratio of -3.13 and a beta of 0.57. The company's 50-day moving average price is $13.10 and its 200-day moving average price is $16.65. Viridian Therapeutics, Inc. has a one year low of $9.90 and a one year high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.95) by $0.08. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The business had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.16 million. The business's revenue was up .0% compared to the same quarter last year. As a group, equities research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on VRDN shares. HC Wainwright restated a "buy" rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. The Goldman Sachs Group cut their target price on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Needham & Company LLC restated a "buy" rating and issued a $36.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, May 20th. Royal Bank of Canada cut their target price on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Finally, JMP Securities cut their target price on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $36.70.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.